CSS
TERN

Cubist Systematic Strategies’s Terns Pharmaceuticals TERN Stock Holding History

Cubist Systematic Strategies’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28,327
Closed -$78.2K – 3512
2025
Q1 		$78.2K Buy
28,327
+16,363
+137% +$66.8K ﹤0.01% 2660
2024
Q4 		$66.3K Sell
11,964
-174,614
-94% -$1.18M ﹤0.01% 2753
2024
Q3 		$1.56M Buy
+186,578
New +$1.54M 0.01% 1566
2024
Q2 		– Sell
-327
Closed -$2.15K – 3992
2024
Q1 		$2.15K Buy
+327
New +$2.13K ﹤0.01% 3575
2023
Q4 		– Sell
-135,015
Closed -$679K – 4102
2023
Q3 		$679K Buy
+135,015
New +$857K 0.01% 2135
2023
Q2 		– Sell
-20,356
Closed -$241K – 4295
2023
Q1 		$241K Buy
20,356
+15,491
+318% +$148K ﹤0.01% 3122
2022
Q4 		$49.5K Buy
+4,865
New +$32.4K ﹤0.01% 3906
2022
Q3 		– Sell
-2,428
Closed -$6K – 4717
2022
Q2 		$6K Buy
2,428
+1,228
+102% +$2.45K ﹤0.01% 4290
2022
Q1 		$4K Buy
+1,200
New +$5.12K ﹤0.01% 3510

Other funds holding TERN

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Cubist Systematic Strategies's TERN Position: Q2 2025 in Review

Cubist Systematic Strategies sold out of Terns Pharmaceuticals (TERN) in Q2 2025, closing a stake of 28,327 shares — an estimated $78.2K sold.

Cubist Systematic Strategies first reported a position in TERN in Q1 2022 and held it in 9 quarters. The position peaked at $1.56M in Q3 2024. 129 funds tracked by Wall St. Rank hold TERN as of Q2 2025.

  • Cubist Systematic Strategies reported no remaining Terns Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Cubist Systematic Strategies sold 28,327 Terns Pharmaceuticals shares in Q2 2025, an estimated $78.2K.
  • Cubist Systematic Strategies first reported a position in Terns Pharmaceuticals in Q1 2022 and held it in 9 quarters.
  • Cubist Systematic Strategies's Terns Pharmaceuticals position peaked at $1.56M in Q3 2024.
  • 129 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2025.

Based on Cubist Systematic Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.